Skip to main content

Defendant Fact Sheet Protocol Released For PPI Lawsuits

Defendant Fact Sheet Protocol Released For PPI Lawsuits

Defendant Fact Sheet Protocol Released For PPI Lawsuits

Introduction

In an order issued on July 30, the federal court overseeing the Proton Pump Inhibitor (PPI) litigation, established the form, procedure, and schedule for the completion and service of Defendant Fact Sheets (DFS).

The court announced that a completed Plaintiff Face Sheet (PFS) must be served by all the defendants either within 120 days from the date of the order's entry or within 120 days from the date on which the PFS is considered complete. If the PFS is served after July 30, the DFS must be served within 90 days from the date of PFS completion. Additionally, the order also states, any defendant can request via an email to the Plaintiffs' Counsel to get a 30 days extension to submit a completed DFS, which cannot be unreasonably withheld by the plaintiff.

The defendants involved in the litigation are AstraZeneca Pharmaceuticals LP, Procter & Gamble Co., McKesson Corp., Takeda Pharmaceuticals USA Inc., Novartis Pharmaceuticals Corp., and Pfizer Inc.

More than 4,700 lawsuits are filed by individuals claiming the PPI manufacturers failed to warn them about kidney failure and other renal complications due to the long-term use of Nexium, Prilosec, PrevAcid, Protonix, or Dexilant. PPI lawsuits were centralized on August 2, 2017, as a part of the multidistrict litigation (MDL No. 2789; In Re: Proton-Pump Inhibitor Products Liability Litigation [No. II]) overlooked by Judge Claire C. Cecchi in the District of New Jersey.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.